Richard Burr: “This Administration has time and again squandered its opportunities and made worse in the decisions you have made on…”

Ms. Kotagal's refusal to continue these common-sense measures speaks volumes of her lack of commitment to due process and transparency.

I am concerned Ms. Kotagal lacks impartiality to interpret the law.

I was surprised and frustrated to hear that these funds were overwhelmingly repurposed from within ASPR, including the stockpile.

What does it mean for a small company when FDA misses these goals, and what does it mean to patients?